Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1749 |
Name | squamous cell carcinoma |
Definition | A carcinoma that derives_from squamous epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5512 |
Path | disease disease of cellular proliferation cancer cell type cancer carcinoma squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | Carboxyamidotriazole Orotate | squamous cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT02383927 | Phase II | Tipifarnib | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | Completed | USA | ITA | FRA | ESP | DEU | BEL | 4 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 4 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Recruiting | CAN | 0 |
NCT03391973 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) | Recruiting | CAN | 0 |
NCT03396471 | Phase II | Pembrolizumab | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | Active, not recruiting | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03669718 | Phase II | Cemiplimab + ISA101b Cemiplimab | A Randomized Phase 2 Study of Cemiplimab +/- ISA101b in HPV16-Positive OPC | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 7 |
NCT03786237 | Phase Ib/II | Rigosertib | Rigosertib for RDEB-SCC | Recruiting | AUT | 0 |
NCT04131621 | Phase II | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) | Unknown status | DEU | 0 |
NCT04666688 | Phase Ib/II | LYT-200 LYT-200 + unspecified PD-1 antibody Gemcitabine + LYT-200 + Nab-paclitaxel | LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Recruiting | USA | 0 |
NCT05472220 | Phase I | Alpelisib + Carboplatin | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | Withdrawn | 0 |